Santhera Pharmaceuticals raises CHF 20 million in growth funding led by R-Bridge and Highbridge Capital Management to accelerate global AGAMREE rollout.
Amount Raised
CHF20 Million
Round Type
Funding Round
PrattelnBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaPharmaceutical ManufacturingpharmaceuticalsInvestors
Description
Santhera Pharmaceuticals has secured CHF 20 million in funding to support the global rollout of AGAMREE. This financing includes USD 13 million from R-Bridge and an additional CHF 10 million from Highbridge. The funds will help increase inventory in China and accelerate launches globally. Demand for AGAMREE continues to exceed expectations across the US, Europe, and China.
Who to call at Santhera Pharmaceuticals, and when
A new round usually means Santhera Pharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Santhera Pharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Santhera Pharmaceuticals, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Santhera Pharmaceuticals. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Santhera Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Santhera Pharmaceuticals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.